Miami, Florida— Global Stem Cells Group, a leader in regenerative medicine, is thrilled to announce a strategic partnership with StemBio, a renowned leader in the regenerative medicine landscape in Turkey. This partnership aims to propel research and development, conduct clinical trials, and create new products and protocols for the advancement of regenerative medicine.

StemBio, a trailblazer in Turkey, possesses all the necessary licenses and state-of-the-art infrastructure for regenerative medicine, including Bone Marrow Derived MSC, Adipose Derived MSC, Umbilical cord, placenta, Wharton jelly Derived MSC, Synovial Derived MSC, and more. We believe this diverse range of resources demonstrates StemBio’s commitment to excellence, making them one of the foremost facilities for regenerative medicine in Turkey.

This collaboration brings together two powerhouses in the regenerative medicine arena, aiming to break new ground in the research, development, and application of regenerative therapies. We believe the collective expertise and resources of StemBio and Global Stem Cells Group are set to drive innovation and advancements in regenerative care, benefiting patients worldwide.

“We are excited to partner with StemBio and leverage their expertise in regenerative medicine. This partnership should accelerate our mission to provide cutting-edge regenerative solutions to a global audience,” said Benito Novas, head of relationships at Global Stem Cells Group.

We believe the partnership between StemBio and Global Stem Cells Group signifies a significant milestone in the regenerative medicine field. As they combine their strengths and knowledge, they are committed to pushing the boundaries of what is possible in regenerative care and making a lasting impact on patients’ lives.

About Global Stem Cells Group:

The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.

GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV.

To learn more about Global Stem Cells Group, Inc.’s companies visit our website or call +1 305 560 5331

About StemBio:

StemBio is a renowned regenerative medicine facility in Turkey, equipped with cutting-edge infrastructure and a commitment to excellence. Holding the necessary licenses for cord blood and tissue banking, as well as advanced engineering solutions, StemBio is a leader in the regenerative medicine landscape.

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Previous Post
Global Stem Cells Group and ReGen Inaugurate New Franchise Clinic in Tashkent, Uzbekistan
Next Post
The International Society for the Application of Stem Cells presents the schedule of International Cellular therapy certifications for 2024.

Latest posts